Teleflex Clears Key Antitrust Hurdle for OEM Divestiture
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Teleflex ( (TFX) ) has provided an announcement.
Teleflex reported that, on December 9, 2025, it entered into an Equity Purchase Agreement to sell its Original Equipment Manufacturing and Development Services business to Lotus US Bidco Inc., an affiliate of Montagu Private Equity and Kohlberg & Co. The Hart-Scott-Rodino antitrust waiting period for this transaction expired at 11:59 p.m. Eastern Time on March 13, 2026, clearing a key regulatory hurdle.
The OEM transaction is now expected to close in the third quarter of 2026, subject to remaining regulatory approvals and customary conditions. On the same date in December 2025, Teleflex also signed a separate Equity Purchase Agreement to divest its Acute Care and Interventional Urology businesses to Intersurgical Limited, underscoring a broader portfolio reshaping that could materially alter the company’s operational focus and market positioning.
The most recent analyst rating on (TFX) stock is a Buy with a $155.00 price target. To see the full list of analyst forecasts on Teleflex stock, see the TFX Stock Forecast page.
Spark’s Take on TFX Stock
According to Spark, TipRanks’ AI Analyst, TFX is a Neutral.
The score is held down primarily by deteriorated TTM financials (sharp revenue decline, large net loss, and negative free cash flow). The earnings outlook is moderately supportive due to guided mid-single-digit growth and clear portfolio actions, but near-term margin/EPS headwinds and execution risk temper confidence. Technicals are mixed with only early signs of improvement, and valuation support is limited by a negative P/E and a modest dividend yield.
To see Spark’s full report on TFX stock, click here.
More about Teleflex
Teleflex Incorporated operates in the medical technology industry, providing specialized equipment and related services for healthcare applications. The company’s portfolio includes original equipment manufacturing and development services, as well as acute care and interventional urology product lines that serve hospitals and clinical providers in global markets.
Average Trading Volume: 940,214
Technical Sentiment Signal: Sell
Current Market Cap: $4.83B
Learn more about TFX stock on TipRanks’ Stock Analysis page.
